Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Prime Medicine (PRME) Accumulated Depreciation & Amortization (2021 - 2025)

Prime Medicine (PRME) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 19.47% year-over-year to $7.3 million, compared with a TTM value of $7.3 million through Dec 2025, up 19.47%, and an annual FY2025 reading of $7.3 million, up 19.47% over the prior year.
  • Accumulated Depreciation & Amortization was $7.3 million for Q4 2025 at Prime Medicine, up from $5.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $7.3 million in Q4 2025 and bottomed at $293000.0 in Q1 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.5 million, with a median of $1.5 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 299.41% in 2022, then tumbled 34.67% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $568000.0 in 2021, then skyrocketed by 291.55% to $2.2 million in 2022, then surged by 109.22% to $4.7 million in 2023, then skyrocketed by 31.7% to $6.1 million in 2024, then increased by 19.47% to $7.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for PRME at $7.3 million in Q4 2025, $5.4 million in Q3 2025, and $1.9 million in Q2 2025.